Balyasny Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $294M | Buy |
10,471,388
+1,926,496
| +23% | +$51.3M | 0.38% | 34 |
|
|
2025
Q4 | $213M | Buy |
8,544,892
+4,026,322
| +89% | +$102M | 0.27% | 63 |
|
|
2025
Q3 | $115M | Buy |
4,518,570
+1,422,123
| +46% | +$35.1M | 0.15% | 139 |
|
|
2025
Q2 | $75.1M | Buy |
3,096,447
+2,592,289
| +514% | +$60.5M | 0.11% | 216 |
|
|
2025
Q1 | $12.8M | Sell |
504,158
-3,286,772
| -87% | -$86M | 0.02% | 786 |
|
|
2024
Q4 | $101M | Buy |
3,790,930
+2,479,836
| +189% | +$67.3M | 0.15% | 150 |
|
|
2024
Q3 | $37.9M | Sell |
1,311,094
-5,133,175
| -80% | -$150M | 0.06% | 400 |
|
|
2024
Q2 | $180M | Buy |
6,444,269
+5,800,893
| +902% | +$160M | 0.32% | 46 |
|
|
2024
Q1 | $17.9M | Sell |
643,376
-1,726,673
| -73% | -$47.9M | 0.03% | 662 |
|
|
2023
Q4 | $68.2M | Sell |
2,370,049
-5,222,829
| -69% | -$158M | 0.13% | 194 |
|
|
2023
Q3 | $252M | Buy |
7,592,878
+7,107,540
| +1,464% | +$251M | 0.51% | 20 |
|
|
2023
Q2 | $17.8M | Buy |
485,338
+296,988
| +158% | +$11.6M | 0.04% | 572 |
|
|
2023
Q1 | $7.68M | Sell |
188,350
-42,557
| -18% | -$1.84M | 0.02% | 887 |
|
|
2022
Q4 | $11.8M | Buy |
230,907
+135,029
| +141% | +$6.47M | 0.03% | 676 |
|
|
2022
Q3 | $4.2M | Buy |
95,878
+66,750
| +229% | +$3.24M | 0.01% | 1093 |
|
|
2022
Q2 | $1.53M | Sell |
29,128
-8,905
| -23% | -$454K | 0.01% | 1552 |
|
|
2022
Q1 | $1.97M | Sell |
38,033
-1,168,797
| -97% | -$60.6M | 0.01% | 1362 |
|
|
2021
Q4 | $71.3M | Buy |
1,206,830
+1,067,959
| +769% | +$52.9M | 0.24% | 76 |
|
|
2021
Q3 | $5.97M | Buy |
+138,871
| New | +$6.15M | 0.02% | 761 |
|
|
2020
Q4 | – | Sell |
-1,554,042
| Closed | -$57M | – | 1604 |
|
|
2020
Q3 | $54.1M | Buy |
1,554,042
+298,982
| +24% | +$10.5M | 0.4% | 45 |
|
|
2020
Q2 | $38.9M | Sell |
1,255,060
-309,244
| -20% | -$10.5M | 0.34% | 62 |
|
|
2020
Q1 | $48.4M | Buy |
+1,564,304
| New | +$53.3M | 0.57% | 25 |
|
|
2019
Q3 | – | Sell |
-6,046
| Closed | -$248K | – | 1484 |
|
|
2019
Q2 | $248K | Sell |
6,046
-2,185,141
| -100% | -$86.8M | ﹤0.01% | 1368 |
|
|
2019
Q1 | $88.3M | Buy |
2,191,187
+2,185,073
| +35,739% | +$87.5M | 0.59% | 16 |
|
|
2018
Q4 | $253K | Sell |
6,114
-450,697
| -99% | -$18.7M | ﹤0.01% | 1263 |
|
|
2018
Q3 | $19.1M | Buy |
456,811
+379,344
| +490% | +$14.6M | 0.09% | 312 |
|
|
2018
Q2 | $2.67M | Sell |
77,467
-55,082
| -42% | -$1.88M | 0.01% | 842 |
|
|
2018
Q1 | $4.46M | Sell |
132,549
-203,650
| -61% | -$7M | 0.02% | 744 |
|
|
2017
Q4 | $11.6M | Buy |
336,199
+230,799
| +219% | +$7.87M | 0.04% | 588 |
|
|
2017
Q3 | $3.57M | Buy |
105,400
+74,834
| +245% | +$2.41M | 0.01% | 817 |
|
|
2017
Q2 | $974K | Sell |
30,566
-400,052
| -93% | -$12.6M | ﹤0.01% | 1112 |
|
|
2017
Q1 | $14M | Buy |
430,618
+339,537
| +373% | +$10.7M | 0.07% | 381 |
|
|
2016
Q4 | $2.81M | Sell |
91,081
-394,877
| -81% | -$12.1M | 0.02% | 825 |
|
|
2016
Q3 | $15.6M | Sell |
485,958
-201,094
| -29% | -$6.72M | 0.09% | 300 |
|
|
2016
Q2 | $23M | Buy |
687,052
+171,862
| +33% | +$5.49M | 0.15% | 178 |
|
|
2016
Q1 | $14.5M | Buy |
515,190
+507,011
| +6,199% | +$14.5M | 0.09% | 309 |
|
|
2015
Q4 | $250K | Sell |
8,179
-3,424,387
| -100% | -$108M | ﹤0.01% | 1026 |
|
|
2015
Q3 | $102M | Buy |
3,432,566
+2,359,503
| +220% | +$75.7M | 0.76% | 14 |
|
|
2015
Q2 | $34.1M | Sell |
1,073,063
-758,390
| -41% | -$24.7M | 0.21% | 119 |
|
|
2015
Q1 | $60.5M | Buy |
1,831,453
+625,553
| +52% | +$19.9M | 0.49% | 36 |
|
|
2014
Q4 | $35.6M | Buy |
+1,205,900
| New | +$34.6M | 0.33% | 79 |
|
Other funds holding PFE
VCM
VPM
Balyasny Asset Management's PFE Position: Q1 2026 in Review
Balyasny Asset Management increased its Pfizer (PFE) stake by 23% in Q1 2026, buying an estimated $51.3M and bringing the position to 10,471,388 shares worth $294M. The position accounts for 0.38% of the portfolio, ranked #34.
Balyasny Asset Management first reported a position in PFE in Q4 2014 and has held it in 41 quarters since. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Balyasny Asset Management held 10,471,388 shares of Pfizer worth $294M as of Q1 2026.
- Balyasny Asset Management bought 1,926,496 Pfizer shares in Q1 2026, an estimated $51.3M.
- Pfizer made up 0.38% of Balyasny Asset Management's portfolio in Q1 2026, its #34 holding.
- Balyasny Asset Management first reported a position in Pfizer in Q4 2014 and has held it in 41 quarters since.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.